Abstract
Purpose
To assess the efficacy and safety of preoperative intravitreal bevacizumab (IVB) before vitrectomy for diabetic tractional retinal detachment (TRD).
Methods
Using ICD-9 codes, we located all patients with diabetic TRD who underwent 3-port 20-gauge vitrectomy primarily performed by one surgeon between January 2004 and January 2009. Eyes receiving IVB were compared with those not. The following outcomes were compared: visual acuity (VA), duration of surgery, and complication rates.
Results
A total of 99 eyes of 90 patients were included in the analysis. In all, 34 patients received IVB on an average of 11.5 (range, 3–30) days previtrectomy. Age was 46.5 and 51.6 in the IVB and non-IVB groups, respectively. VA was improved significantly in both groups: from 20/617 to 20/62 in the IVB group, and from 20/443 to 20/86 in the non-IVB group (P=0.11 between groups). Operating time and postoperative complications (glaucoma, RD, and revitrectomy rate) were similar in both groups. On comparing IVB and non-IVB eyes in younger patients (≤40), operating time was shorter (P=0.02) and a trend to better VA in the IVB group was seen.
Conclusions
Preoperative IVB may be a useful adjunct to vitrectomy for severe PDR complicated by TRD, particularly in younger diabetics.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Diabetic Retinopathy Vitrectomy Study Research Group. Two-year course of visual acuity in severe proliferative diabetic retinopathy with conventional management. Diabetic Retinopathy Vitrectomy Study Report #1. Ophthalmology 1985; 92: 492–502.
Mason JO, Colagross CT, Haleman T, Fuller JJ, White MF, Feist RM et al. Visual outcome and risk factors for light perception and no light perception vision after vitrectomy for diabetic retinopathy. Am J Ophthalmol 2005; 140: 231–235.
Chen E, Park CH . Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina 2006; 26: 699–700.
Rizzo S, Genovesi-Ebert F, Di Bartolo E, Vento A, Miniaci S, Williams G . Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). Graefes Arch Clin Exp Ophthalmol 2008; 246: 837–842.
Yeoh J, Williams C, Allen P, Buttery R, Chiu D, Clark B et al. Avastin as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy: a prospective case series. Clin Experiment Ophthalmol 2008; 36: 449–454.
Oshima Y, Shima C, Wakabayashi T, Kusaka S, Shiraga F, Ohji M et al. Microincision vitrectomy surgery and intravitreal bevacizumab as a surgical adjunct to treat diabetic traction retinal detachment. Ophthalmology 2009; 116: 927–938.
Lo WR, Kim SJ, Aaberg Sr TM, Bergstrom C, Srivastava SK, Yan J et al. Visual outcomes and incidence of recurrent vitreous hemorrhage after vitrectomy in diabetic eyes pretreated with bevacizumab (Avastin). Retina 2009; 29: 926–931.
da R Lucena D, Ribeiro JA, Costa RA, Barbosa JC, Scott IU, de Figueiredo-Pontes LL et al. Intraoperative bleeding during vitrectomy for diabetic tractional retinal detachment with versus without preoperative intravitreal bevacizumab (IBeTra study). Br J Ophthalmol 2009; 93: 688–691.
Romano MR, Gibran SK, Marticorena J, Wong D, Heimann H . Can a preoperative bevacizumab injection prevent recurrent postvitrectomy diabetic vitreous haemorrhage? Eye 2009; 23: 1698–1701.
Ishikawa K, Honda S, Tsukahara Y, Negi A . Preferable use of intravitreal bevacizumab as a pretreatment of vitrectomy for severe proliferative diabetic retinopathy. Eye 2009; 23: 108–111.
Modarres M, Nazari H, Falavarjani KG, Naseripour M, Hashemi M, Parvaresh MM . Intravitreal injection of bevacizumab before vitrectomy for proliferative diabetic retinopathy. Eur J Ophthalmol 2009; 19: 848–852.
di Lauro R, De Ruggiero P, di Lauro R, di Lauro MT, Romano MR . Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2010; 248: 785–791.
Yang CM, Yeh PT, Yang CH, Chen MS . Bevacizumab pretreatment and long-acting gas infusion on vitreous clear-up after diabetic vitrectomy. Am J Ophthalmol 2008; 146: 211–217.
Ahmadieh H, Shoeibi N, Entezari M, Monshizadeh R . Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients a randomized clinical trial. Ophthalmology 2009; 116: 1943–1948.
Arevalo JF, Maia M, Flynn Jr HW, Saravia M, Avery RL, Wu L et al. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol 2008; 92: 213–216.
Moradian S, Ahmadieh H, Malihi M, Soheilian M, Dehghan MH, Azarmina M . Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2008; 246: 1699–1705.
Jonas JB, Schmidbauer M, Rensch F . Progression of tractional retinal detachment following intravitreal bevacizumab. Acta Ophthalmol 2009; 87: 571–572.
Lee SJ, Koh HJ . Enlargement of the foveal avascular zone in diabetic retinopathy after adjunctive intravitreal bevacizumab (Avastin) with pars plana vitrectomy. J Ocul Pharmacol Ther 2009; 25: 173–174.
Chen E, Hsu J, Park CH . Acute visual acuity loss following intravitreal bevacizumab for diabetic macular edema. Ophthalmic Surg Lasers Imaging 2009; 40: 68–70.
Holladay JT . Visual acuity measurements. J Cataract Refract Surg 2004; 30: 287–290.
Acknowledgements
Russell Pokroy received fellowship grants from the American Physicians Fellowship for Medicine in Israel, and from the Israel Ophthalmic Society.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Meeting presentations: Presented in part at the Retina Congress 2009, New York, NY, October 2009.
Rights and permissions
About this article
Cite this article
Pokroy, R., Desai, U., Du, E. et al. Bevacizumab prior to vitrectomy for diabetic traction retinal detachment. Eye 25, 989–997 (2011). https://doi.org/10.1038/eye.2011.149
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/eye.2011.149
Keywords
This article is cited by
-
Pre-operative intravitreal bevacizumab for tractional retinal detachment secondary to proliferative diabetic retinopathy: the Alvaro Rodriguez lecture 2023
International Journal of Retina and Vitreous (2023)
-
Approaches to the Repair of Diabetic Traction Retinal Detachments
Current Surgery Reports (2022)
-
Sickle cell retinopathy. A focused review
Graefe's Archive for Clinical and Experimental Ophthalmology (2019)
-
Bevacizumab as an adjunct to vitreoretinal surgery for diabetic retinopathy in East Africa
Eye (2013)
-
Six-month visual outcome after pars plana vitrectomy in proliferative diabetic retinopathy with or without a single preoperative injection of intravitreal bevacizumab
International Ophthalmology (2012)
